Scancell Holdings plc (LON:SCLP – Get Free Report) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 13.72 ($0.17) and traded as low as GBX 10.77 ($0.14). Scancell shares last traded at GBX 11.10 ($0.14), with a volume of 100,543 shares.
Scancell Stock Up 0.9 %
The company has a market cap of £103.19 million, a PE ratio of -1,110.00 and a beta of 0.35. The business has a 50-day simple moving average of GBX 13.12 and a 200-day simple moving average of GBX 13.72. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of 61.41.
About Scancell
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer.
Further Reading
- Five stocks we like better than Scancell
- ESG Stocks, What Investors Should Know
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- 2 Drone Stocks Surging from Increased Media Attention
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
